Venous Ulcers

Varithena® improves the underlying symptoms of C5/C6 venous disease.


With Varithena® you can treat the symptoms of the underlying problem. As an FDA approved Microfoam UDSS™ Procedure, Varithena® can go where wire-based ablation devices cannot. Varithena® can treat the veins that feed the ulcer and address the underlying venous incompetence above and below the knee.12,13

Before & After Photos

These photos show results after one treatment with Varithena®.
Additional treatment may be needed, depending on the number and size of veins to be treated.
Your results may vary

  • Varithena® is indicated for the treatment of the great saphenous vein (GSV) system above and below the knee.
  • Varithena® treats the underlying venous insufficiency associated with C6 venous disease
  • Varithena® has shown positive outcomes improving symptoms in C5/C6 patients12
  • Varithena® has an established safety profile for the C2-C6 population in clinical trials

To learn more about how Varithena works, view this video.

Did you know?

  • 1 in 4 Americans 65+ will suffer from C6 venous disease in their lifetime12
  • Costs each patient $17k-$23k annually13
  • Costs the healthcare system $10B+ annually13
  • Up to 70% of C6 venous ulcers recur 3 months after healing14

“The impact of a C5/C6 venous disease represents social, personal, financial and psychological costs on the individual and further economic drain on the health-care system.14


Contact your
Territory Sales Manager

Contact Customer Service at

1-855-971-VEIN (8346)

Monday through Friday,
8 am to 5 pm ET


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

This website is intended for visitors from the United States.


Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.


The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.